Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 65 Stomach Neoplasms 14 Colonic Neoplasms 10 Rectal Neoplasms 5 Triple Negative Breast Neoplasms 3 Sarcoma 3 Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Neoplasm Metastasis 2 NSCLC 2 Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Colorectal Cancer Metastatic 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Advanced Solid Tumors 2 Advanced Colorectal Carcinoma 2 Unresectable Metastatic Colorectal Cancer 1 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 TAS 102 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Platinum Resistant Ovarian Cancer 1 Patients With Advanced Metastatic Colorectal Cancer 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasm, Residual 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Metastatic Colorectal Adenocarcinoma 1

Interventions

Carboplatin 346 Cisplatin 240 Paclitaxel 208 Radiotherapy 207 Pemetrexed 190 Docetaxel 170 Gemcitabine 158 pembrolizumab 147 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 102 Etoposide 99 Bevacizumab 96 Specimen Handling 84 Nivolumab 77 Radiosurgery 74 durvalumab 73 Blood Specimen Collection 65 Drug Therapy 61 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 48 atezolizumab 45 Biopsy 43 Radiation 42 Irinotecan 42 Topotecan 39 Standard of Care 39 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × HMPL-013 × Clear all

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Hutchmed

Phase 2 Withdrawn

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡